1272 related articles for article (PubMed ID: 21353695)
1. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
[TBL] [Abstract][Full Text] [Related]
4. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
Barrett-Lee P; Casbard A; Abraham J; Hood K; Coleman R; Simmonds P; Timmins H; Wheatley D; Grieve R; Griffiths G; Murray N
Lancet Oncol; 2014 Jan; 15(1):114-22. PubMed ID: 24332514
[TBL] [Abstract][Full Text] [Related]
5. Bone health and prostate cancer.
Saylor PJ; Smith MR
Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):20-7. PubMed ID: 19901958
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid.
Vadhan-Raj S; von Moos R; Fallowfield LJ; Patrick DL; Goldwasser F; Cleeland CS; Henry DH; Novello S; Hungria V; Qian Y; Feng A; Yeh H; Chung K
Ann Oncol; 2012 Dec; 23(12):3045-3051. PubMed ID: 22851406
[TBL] [Abstract][Full Text] [Related]
7. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Himelstein AL; Foster JC; Khatcheressian JL; Roberts JD; Seisler DK; Novotny PJ; Qin R; Go RS; Grubbs SS; O'Connor T; Velasco MR; Weckstein D; O'Mara A; Loprinzi CL; Shapiro CL
JAMA; 2017 Jan; 317(1):48-58. PubMed ID: 28030702
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapies to prevent skeletal morbidity in men with prostate cancer.
Saylor PJ; Lee RJ; Smith MR
J Clin Oncol; 2011 Sep; 29(27):3705-14. PubMed ID: 21860001
[TBL] [Abstract][Full Text] [Related]
9. New and emerging therapies for bone metastases in genitourinary cancers.
Saylor PJ; Armstrong AJ; Fizazi K; Freedland S; Saad F; Smith MR; Tombal B; Pienta K
Eur Urol; 2013 Feb; 63(2):309-20. PubMed ID: 23201471
[TBL] [Abstract][Full Text] [Related]
10. Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.
Fizazi K; Massard C; Smith M; Rader M; Brown J; Milecki P; Shore N; Oudard S; Karsh L; Carducci M; Damião R; Wang H; Ying W; Goessl C
Eur Urol; 2015 Jul; 68(1):42-50. PubMed ID: 25449207
[TBL] [Abstract][Full Text] [Related]
11. Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.
Smith MR
Urol Oncol; 2008; 26(4):420-5. PubMed ID: 18593621
[TBL] [Abstract][Full Text] [Related]
12. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
Saad F; Brown JE; Van Poznak C; Ibrahim T; Stemmer SM; Stopeck AT; Diel IJ; Takahashi S; Shore N; Henry DH; Barrios CH; Facon T; Senecal F; Fizazi K; Zhou L; Daniels A; Carrière P; Dansey R
Ann Oncol; 2012 May; 23(5):1341-1347. PubMed ID: 21986094
[TBL] [Abstract][Full Text] [Related]
13. Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer.
Mitchell AP; Nemirovsky D; Mishra Meza A; Chakraborty N; Persaud S; Farooki A; Morris MJ
JCO Oncol Pract; 2024 Mar; 20(3):393-400. PubMed ID: 38190588
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
Shapiro CL; Moriarty JP; Dusetzina S; Himelstein AL; Foster JC; Grubbs SS; Novotny PJ; Borah BJ
J Clin Oncol; 2017 Dec; 35(35):3949-3955. PubMed ID: 29023215
[TBL] [Abstract][Full Text] [Related]
15. Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.
Wang Z; Qiao D; Lu Y; Curtis D; Wen X; Yao Y; Zhao H
Oncologist; 2015 Apr; 20(4):440-9. PubMed ID: 25732263
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
Andronis L; Goranitis I; Pirrie S; Pope A; Barton D; Collins S; Daunton A; McLaren D; O'Sullivan JM; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown JE; Chakraborti P; Hussain SA; Russell JM; Billingham LJ; James ND
BJU Int; 2017 Apr; 119(4):522-529. PubMed ID: 27256016
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.
Autio KA; Scher HI; Morris MJ
Curr Treat Options Oncol; 2012 Jun; 13(2):174-88. PubMed ID: 22528368
[TBL] [Abstract][Full Text] [Related]
18. Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases.
von Moos R; Body JJ; Egerdie B; Stopeck A; Brown J; Fallowfield L; Patrick DL; Cleeland C; Damyanov D; Palazzo FS; Marx G; Zhou Y; Braun A; Balakumaran A; Qian Y
Support Care Cancer; 2016 Mar; 24(3):1327-37. PubMed ID: 26329397
[TBL] [Abstract][Full Text] [Related]
19. Treatment Patterns of Bone-targeting Agents Among Solid Tumor Patients With Bone Metastases: An Analysis of Electronic Health Record Data in the United States From 2014 to 2018.
Nicholson G; Carlson KB; Hernandez RK; Schenfeld J; Cadieux B; Henry D; De Sousa Barbosa VJ; Saad H
Am J Clin Oncol; 2024 Apr; 47(4):177-184. PubMed ID: 38200688
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness Analysis of Denosumab in the Prevention of Skeletal-Related Events Among Patients With Breast Cancer With Bone Metastasis in India.
Wadhwa R; Gupta N; Dixit J; Malhotra P; Lakshmi P; Prinja S
JCO Glob Oncol; 2024 Mar; 10():e2300396. PubMed ID: 38452304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
